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Abstract Des-aspartate-angiotensin I (DAA-I) is an
endogenous angiotensin peptide and a prototype angio-
tensin receptor agonist (ARA). It acts on the angiotensin
AT1 receptor and antagonises the deleterious actions of
angiotensin II. DAA-I attenuates animal models of human
disease in which angiotensin II has been implicated, such
as cardiac hypertrophy, neointima formation, arterioscle-
rosis, renal failure, post-infarction injuries, diabetes, viral
infection, chemical-induced inflammation, heat stroke,
cancer, and gamma radiation lethality. DAA-I crosses
Caco-2 cells and is effective at sub-nanomolar concentra-
tions. These two properties are responsible for its oral
efficacy. A single dose-escalation study was conducted to
evaluate the safety, tolerability and pharmacokinetics of
orally administered DAA-I in 18 healthy subjects. DAA-I
was safe and well tolerated by the subjects, who were
administered either 0.08, 0.70 or 1.50 mg/kg of the com-
pound. The heart rate and systolic and diastolic blood
pressures determined at each post-dose measurement
remained within the clinically acceptable range. Across all
cohorts, DAA-I had no substantial effect on blood pres-
sures compared with placebo. Electrocardiographs (ECGs)
were normal, and none of the subjects complained of chest
discomfort. All clinical laboratory tests obtained before and
after DAA-I and placebo treatment were normal. Pharma-
cokinetic analysis over a 12-h period following DAA-I
administration did not show any increase of its level
beyond basal concentration. This is in line with studies
showing that intravenously administered DAA-I is rapidly
metabolized and has a short half-life. We postulate that,
during its short systemic sojourn, DAA-I exerts its actions
via biased agonism on the angiotensin AT1 receptor.
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Key Points
The safety, tolerability, and pharmacokinetics of des-
aspartate-angiotensin I (DAA-I), an endogenous
angiotensin peptide, were studied in 18 subjects (12
DAA-I treated and 6 placebo).
DAA-I was well tolerated, and all DAA-I-treated
subjects did not experience untoward effects or show
abnormal clinical test readings when administered
with 0.08, 0.7, 1.5 mg/kg of the peptide.
Plasma level of DAA-I determined during the 12-h
postadministration period was not significantly
different from basal level, and this was due to its
rapid degradation by blood enzymes, as shown in
earlier preclinical studies.
Earlier studies showed that DAA-I was efficacious in
seven animal models of human disease. We postulate
the same efficacies for human, and that DAA-I acts
as a biased agonist on the angiotensin AT1 receptor
at ultra low doses prior to its degradation in the
circulation.
1 Introduction
Des-aspartate angiotensin I (DAA-I) is a functional
angiotensin peptide that acts as an agonist on the angio-
tensin AT1 receptor and elicits responses opposing those of
angiotensin II. Accordingly, DAA-I has been shown to be
efficacious in animal models of cardiac hypertrophy [1],
neointima formation [2], arteriosclerosis [2], renal failure
[3], post-infarction injuries [4, 5], diabetes [6, 7], viral
infection [8], chemical-induced inflammation [9], heat
stroke [10], cancer [10] and gamma radiation lethality [11],
where it has been found to significantly attenuate the
severity of the pathology. At effective doses, DAA-I has no
observable effects on the basal physiological and bio-
chemical parameters that were measured in these studies
and was found to lack secondary responses that could be
considered adverse or side effects. At the cellular level,
DAA-I is known to exert anti-inflammatory actions [10].
Binding of DAA-I to the angiotensin AT1 receptor releases
prostaglandins, which function as autocrines and/or second
messengers [12]. In human umbilical vein endothelial cells,
DAA-I specifically released prostaglandin E2 (PGE2) and
PGI2 via cyclooxygenase (COX)-1 at sub-nanomolar con-
centrations. The release of PGE2 and PGI2 via the angio-
tensin AT1 receptor and COX-1 was identified as a novel
action specific to DAA-I [13], and it is likely that the
beneficial effects of DAA-I are mediated by the two
prostaglandins. This specific action is definable as a biased
agonism of the angiotensin AT1 receptor, which identifies
DAA-I as a novel biased agonist and potential therapeutic
able to produce specific prostaglandins at sub-nanomolar
concentrations [13].
A specific aminopeptidase has been shown to cleave
aspartate from angiotensin I to form DAA-I, a nine amino
acid peptide consisting of Arg-Val-Tyr-Ile-His-Pro-Phe-
His-Leu [14, 15]. Its level in human plasma has been
estimated to be 19.5 pmole/l [16]. When infused into dogs
[17] and human subjects [18], DAA-I is rapidly metabo-
lised by blood angiotensin-converting enzyme (ACE) to
angiotensin III and to angiotensin IV and smaller inactive
peptide fragments by blood peptidases. However, active
concentrations above the basal level are achievable with
orally administered DAA-I. This is because DAA-I is
active at sub-nanomolar concentrations, and these con-
centrations are 1000-fold lower than the Km of most
enzymes [12]. The angiotensin AT1 receptors rapidly
internalize upon ligand binding, and this is likely to result
in sufficient amounts of DAA-I entering target tissues.
DAA-I has been shown to cross the Caco-2 monolayer via
passive diffusion, indicating it could cross intestinal
epithelial cells [19].
DAA-I constitutes a new member of the class of drugs
that act by attenuating the deleterious actions of angio-
tensin II. The other well-known members of this class are
the ACE inhibitors, which act by attenuating the formation
of angiotensin II; and the angiotensin receptor blockers
(ARBs), which act as receptor antagonists of angiotensin II.
However, unlike ACE inhibitors and ARBs, DAA-I is a
prototype angiotensin AT1 receptor agonist (ARA) [12].
The toxicological profile obtained from the preclinical
studies is favourable to the study of DAA-I in human
subjects. The findings from non-clinical pharmacological
studies are equally predictive of its oral efficacy in human
subjects. Hence, the desire to conduct a single-dose phase I
clinical trial of DAA-I. The primary objective of this study
was to evaluate the safety and dose range of DAA-I after
administration of a single oral dose to healthy individuals.
The secondary objective was to evaluate the pharmacoki-
netics of DAA-I after single oral dose administration.
Overall, the present study is a prelude and prerequisite to a
multi-dose phase I study of DAA-I.
2 Methods
2.1 Regulatory Approval
The clinical study protocol, subject information sheets,
written inform consent forms and all other relevant study
documents were reviewed and approved by the responsible
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Institutional Review Board (Health Science Authority,
Singapore) and Ethics Review Board (Domain Specific
Review Boards, Singapore). The study was conducted
under the principles set forth in the Declaration of Helsinki
and the guidelines of the International Conference on
Harmonization (ICH) on Good Clinical Practice (GCP) and
was monitored by the Singapore Clinical Research Insti-
tute. All subjects were informed of the nature, purpose and
requirements of the study, and their written informed
consent was obtained prior to the pre-study screening
procedures. The study was conducted at the Investigation
Medicine Unit of the National University Health System,
Singapore.
2.2 Subject and Recruitment
Healthy males and females, aged 21–50 years (inclusive),
with body mass index (BMI) of 19–30 kg/m2 were
recruited into the study after screening. Table 1 summa-
rizes the clinical characteristics of the study subjects.
2.3 Study Drug
DAA-I was synthesized by BACHEM AG, Switzerland,
according to Good Manufacturing Practice (GMP) and
packed as a solid compound in vials containing 7.1, 59.2
and 130.3 mg per vial. The purity of DAA-I was 99.7 %
with a shelf life of 2 years when stored desiccated at 4 C.
DAA-I was prepared for oral administration by dissolving
the solid compound in each vial with 25 ml of sterile water
on the day of need. The correct weight-adjusted dose was
made by adjusting the volume of the dissolved DAA-I
given to each subject. The appropriate volume of DAA-I
solution was drunk by the subject while standing, and this
was followed by the subject drinking another 200 ml of
sterile water.
2.4 Study Design
The trial was a placebo-controlled randomized phase I
study to investigate the safety and pharmacokinetics of
DAA-I in 18 healthy subjects. The study was single-blind,
and dose escalation was performed in a step-wise manner
of up to three dose levels of DAA-I. In this sequential
stepwise design, a single dose of DAA-I or placebo was
administered to six subjects per treatment group. For each
dose level, four subjects received DAA-I and two subjects
received placebo (sterile water) in a randomized manner.
There was an interval of 6 h between the dosing of the first
and second DAA-I-treated subjects of each cohort to allow
for early cardiovascular monitoring. The remaining sub-
jects were simultaneously dosed after the investigators had
established safety in the clinical monitoring following the
first dose. Dose escalation to the next level was only
allowed upon completion of the preceding dose level and
following review of the safety results from the preceding
dose level(s).
2.5 Study Schedule
The subjects attended a screening visit, a stay-in study
period of 2 days and 2 nights and a follow-up visit at the
trial site. Screening visits were conducted between day –28
to day -1 of the trial. The trial procedures performed at the
screening visits included the following: (1) signing of
written informed consent; (2) physical examination, med-
ical history, measurement of weight and height; (3)
assessment of vital signs (blood pressure, heart rate, pulse
oximetry, body temperature and breathing rate); (4) full
blood count; (5) renal function test (serum creatinine
levels, albumin, blood urea nitrogen, phosphorus, potas-
sium, sodium and glucose); (6) liver function tests (alanine
aminotransferase [ALT], aspartate aminotransferase
[AST], alkaline phosphatase [ALP], lactate dehydrogenase
[LDH], and bilirubin); (7) urinalysis, urine pregnancy test
(for females with child-bearing potential); and (8) 12-lead
electrocardiogram (ECG).
Eligible subjects were admitted to the trial centre on day
–1. The subjects were sent to bed by 22:00 h, and no food
was allowed from 12 midnight onwards. Subjects were
woken up at 07:00 h on day 1. Before administration of the
study drug, a brief physical examination, vital sign
Table 1 Baseline demographics and clinical characteristics of study
subjects
Characteristics
Continuous variables, N = 18
Age (years) 35 ± 7 (24–47)
Height (cm) 173 ± 7 (161–188)
Weight (kg) 70 ± 12.6 (52.3–89.4)
BMI (kg/m2) 23.4 ± 2.8 (19.1–30.0)
Systolic pressure (mmHg) 116 ± 11 (100–138)
Diastolic pressure (mmHg) 69 ± 9 (56–87)
Mean arterial pressure (mmHg) 85 ± 9 (73–104)








Data are presented as mean ± standard deviation or n (%)
BMI body mass index, SD standard deviation
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assessment and 12-lead ECG were performed. Blood was
then sampled for full blood count, renal and liver function
tests, urinalysis, random glucose and urine pregnancy test
(if applicable) and aldosterone test. Each subject was
cannulated for pharmacokinetic blood sampling. At
08:00 h, the subjects received the assigned study drug
(DAA-I or placebo), and no food intake was allowed 2 h
following drug or placebo administration. Water intake
was allowed up to a maximum of 200 ml.
Vital signs were assessed at 0.25, 0.5, 0.75, 1, 2, 3, 4, 5,
6, 12 and 24 h post dose, and 12-lead ECG was conducted
at 1, 3, 6 and 12 h post dose. Blood samples were collected
at 24 h post dose for determination of full blood count,
liver function tests and renal function tests. Blood glucose
was measured in blood samples at 2, 3, 4, 5 and 6 h fol-
lowing drug or placebo administration, and an aldosterone
test was performed at 1 and 4 h post dose. The subjects
were discharged on day 2 and returned to the trial centre
the following day for follow-up assessment.
2.6 Pharmacokinetic Measurement
Serial venous blood samplings (10 ml) for pharmacokinetic
analyseswere carried out on all subjects at 0, 0.25, 0.5, 1, 2, 3,
4, 5, 6 and 12 h post study drug administration. We antici-
pated that the range of sampling time points would cover the
duration of early blood pressure response to intravenous
administration of DAA-I observed in human subjects [18],
and the detection of chromatographic [14]C-DAA-I-like peak
at 4 h after [14]C-DAA-I was orally administered to rats
during the preclinical toxicology studies.
Each 10 ml of collected blood sample was immediately
transferred to a centrifuge tube containing 200 ll of an
aqueous solution of 50 mM EDTA and 50 mM captopril
and gently mixed to prevent the degradation of DAA-I by
blood ACE and peptidases. Captopril and EDTA are
inhibitors of ACE, and EDTA is an inhibitor of peptidases.
Plasma was collected by immediately centrifuging the
mixture at 4 C and stored at –20 C for batch analysis.
The plasma samples were analysed for DAA-I concen-
trations using an Agilent 1290 Infinity Binary UHPLC
system coupled to an Agilent 6495 triple quadrupole MS/
MS system. An Agilent Poroshell SB-C18 column
(50 mm 9 3 mm, 2.7 lm particle size) was used for
chromatography set at 40.0 C. For MS detection, an ESI
ion source operating in positive ion mode was used for all
analyses. The Agilent Masshunter software, version
B.06.00, was used for data collection. The method was
validated for a concentration range of 25 pg/ml (lower
limit of quantification [LLOQ]) and 1000 pg/ml (upper
limit of quantification [ULOQ]) according to ICH guide-
lines on accuracy, precision (repeatability), linearity, range
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2.7 Statistical Analysis and Analysis of Measured
Clinical Parameters
We employed analysis of variance (ANOVA) to test for
significant difference between the grouped area under the
plasma concentration–time curve (AUC) of the 12 subjects
who were administered DAA-I and the grouped AUC of
the six subjects who were administered placebo. A
p\ 0.05 indicates significance. The normal range of values
of the College of American Pathologists checklist was used
to categorise all laboratory tests.
3 Results
A total of 18 healthy subjects (17 males and 1 female) aged
24–47 years enrolled and participated in this study
(Table 1). All subjects, except one, were Chinese, which
reflects the predominantly Chinese demographics of Sin-
gapore. No subjects withdrew, and all 18 subjects complied
with the trial procedures and completed the study.
3.1 Safety and Tolerability
DAA-I was safe and well tolerated by the subjects. No
adverse event was observed in the subjects who were
administered either 0.08, 0.70 or 1.50 mg/kg of DAA-I.
The vital signs (heart rate, systolic and diastolic blood
pressure, pulse oximetry, body temperature and breathing
rate) determined at each post-dose measurement remained
within the clinically acceptable range. Table 2 shows the
values of the vital signs obtained at 0 h (pre-dose) and 24 h
post dose. Across all cohorts, DAA-I had no substantial
effect on blood pressures compared with placebo. ECGs
were normal, and none of the subjects complained of chest
discomfort. The level of aldosterone in the plasma of the 18
subjects obtained before DAA-I or placebo administration
and at 1 and 4 h post-administration were within the nor-
mal range (Table 3). All other clinical laboratory tests
obtained before and after DAA-I and placebo treatment
were normal. The results of the liver function test, renal
function test and urinalysis carried out at 0 h (pre-dose)
and 24 h post dose are displayed in Tables 4, 5 and 6,
respectively.
3.2 Pharmacokinetics
The concentration of DAA-I in the ten plasma samples
obtained from each subject was determined and plotted
against the sampling time to obtain the AUC. Figure 1
displays the mean AUC of the four DAA-I-treated and two
placebo-treated subjects in each of the three subject
cohorts. Subjects who were administered DAA-I did not
show any specific DAA-I plasma profile that differed from
the corresponding profile of the placebo subjects. The value
of each AUC was determined by the trapezoid method and
is displayed in Table 7. The AUC of the DAA-I-treated
subjects was compared with that of the placebo-treated
subjects by one-way ANOVA for statistical difference.
There was no significant difference in the AUC between
the two groups for the three doses of DAA-I.
4 Discussion
Kono et al. [18] demonstrated that increases in blood
pressure and plasma aldosterone were the immediate
responses to an intravenous infusion of DAA-I in human
subjects. Hence, data obtained from blood pressure and
ECG monitoring and plasma aldosterone determination
conducted in this study would provide indications of
adverse responses arising from the oral administration of
DAA-I. The data obtained from subjects who received
either one of the three oral doses of DAA-I (0.08, 0.7 and
1.5 mg/kg) were either within normal ranges or absent of
any abnormal pattern. The oral dose of 1.5 mg/kg is more
than two times the maximum effective hypoglycaemic dose
of DAA-I (0.71 mg/kg or 600 nmole/kg) that has been
shown to attenuate insulin resistance [6, 7] and mediators
of chronic inflammation in animal models of type 2 dia-
betes [7]. These show that DAA-I is safe and well tolerated
in human subjects and could be administered at the antic-
ipated anti-diabetic dose of 0.71 mg/kg to patients with
diabetes. This premise is supported by data from an earlier
Table 3 Blood aldosterone
level
Time 0 h pre dose 1 h post dose 4 h post dose
Placebo 340 ± 121 (196–511) 206 ± 112 (112–345) 280 ± 103 (390–95)
DAA-I (0.08 mg/kg) 261 ± 95 (160–354) 167 ± 66 (87–241) 239 ± 145 (113–461)
DAA-I (0.7 mg/kg) 351 ± 178 (185–597) 179 ± 64 (110–236) 166 ± 66 (103–248)
DAA-I (1.5 mg/kg) 340 ± 197 (86–512) 199 ± 62 (108–244) 213 ± 60 (135–282)
Data are presented as mean ± standard deviation (range). All values are within the normal range of
\445 pmol/l
DAA-I des-aspartate-angiotensin I
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preclinical study showing that the heart rate and blood
pressure (tracked by telemetry monitoring) of conscious
freely moving rats were not affected by a single oral dose
of DAA-I given as 5, 10, and 20 lmole/kg (5.9, 11.8 and
23.6 mg/kg) (unpublished preclinical toxicological data).
When intravenously administered into rats, DAA-I is
rapidly degraded by plasma enzymes within 2–5 min (un-
published preclinical toxicological data). Other investiga-
tors have reported similar short durations in systemic
circulation following an intravenous administration of the
compound in dogs [17] and human subjects [18]. The
present study shows there was no increase in circulating
DAA-I in subjects who received oral DAA-I at doses
shown to be effective in attenuating animal models of
human disease. Although this observation seems to be a
discrepancy, it is not unexpected, as the rapid metabolism
of absorbed DAA-I by blood enzymes would again result in
a short systemic sojourn, the duration of which could be
shorter than the blood sampling time of 2–3 min and the
blood sampling interval of 15 min. Despite its rapid
degradation and short systemic sojourn, DAA-I is effective
in combating animal models of human disease when
administered either intravenously or orally [12]. Two major
mechanisms are likely involved. First, in certain in situ
preparations where the circulating blood was replaced with
physiological solution, DAA-I was effective at ultra-low
concentrations that are below the Km of enzymes. At femto
(10-15) molar concentration, DAA-I has been shown to
attenuate the pressor actions of angiotensin III in the renal
and mesenteric vasculature of the spontaneously hyper-
tensive rat [20], and at atto (10-18) molar concentration, to
attenuate the pressor actions of angiotensin II in similar
vascular beds of the normo- and hypertensive rats [21].
Being effective at concentrations lower than the Km of
Fig. 1 Plot of averaged plasma DAA-I concentration vs. sampling
time. Top panel plot of cohort 1 subjects who received either
0.08 mg/kg DAA-I (four subjects) or placebo (two subjects). Middle
panel plot of cohort 2 subjects who received either 0.70 mg/kg DAA-
I (four subjects) or placebo (two subjects). Bottom panel plot of
cohort 3 subjects who received either 1.5 mg/kg DAA-I (four
subjects) or placebo (two subjects)
Table 7 Area under the plasma
concentration versus time curve
of placebo and DAA-I-treated
subjects (AUC)
Dose level AUC (pg 12 h/ml)
Subject 1 Subject 2 Subject 3 Subject 4 Subject 5 Subject 6 Mean ± SD
Level 1 (0.08 mg/kg)
Placebo 85,595 64,390 – – – – 74,993 ± 14,994
DAA-I – – 15,2282 50,802 58,768 54,301 79,038 ± 48,938
Level 2 (0.70 mg/kg)
Placebo 75,724 56,454 – – – – 66,089 ± 13,626
DAA-I – – 48,953 45,813 65,180 73,266 58,303 ± 13,097
Level 3 (1.50 mg/kg)
Placebo 89,986 95,223 – – – – 92,605 ± 3703
DAA-I – – 81,675 76,230 92,276 88,237 84,605 ± 7089
Blood was sampled before oral administration of DAA-I or placebo and at 0.25, 0.50, 1, 2, 3, 4, 5, 6 and
12 h after administration. The AUC measures the amount of DAA-I in systemic circulation during the 12 h
following administration. There was no significant difference between the grouped AUC of the 12 subjects
who received DAA-I and the grouped AUC of the six subjects who received placebo (p = 0.764, ANOVA)
ANOVA analysis of variance, AUC area under the plasma concentration–time curve, DAA-I des-aspartate-
angiotensin I, SD standard deviation
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enzymes (the Km of most enzymes is 10-6 M), our earlier
studies have shown that substantial effective concentra-
tions of DAA-I could be attained either by the intravenous
or oral route of administration [12]. In a study where both
intravenous and oral DAA-I were shown to produce similar
magnitudes of attenuation of cardiac hypertrophy, an oral
bioavailability of 0.06 was shown to account for its anti-
cardiac hypertrophy action [12]. DAA-I has been shown to
cross the Caco-2 monolayer via passive diffusion [19],
indicating it would cross intestinal epithelial cells. The
second mechanism is the rapid internalization (within
minutes) of the G-protein-coupled receptor (which includes
the angiotensin AT1 receptor) upon ligand binding [22, 23].
Pharmacodynamic and efficacy studies show that DAA-I
exerts its action by acting as an agonist on the angiotensin
AT1 receptor [12]. Upon the binding of DAA-I to the AT1
receptor, the receptor internalizes and the DAA-I/receptor
complex has been shown to remain active and to specifi-
cally release PGE2 and PGI2 [13]. Glucagon-like peptide
(GLP)-1, which binds to the GLP-1 receptor (another
G-protein-coupled receptor) and internalizes [24], has also
been shown to be active after its blood level has returned to
circulating levels following cessation of administration via
osmotic pump [25]. Like DAA-I, GLP-1 is rapidly
metabolized in the circulation and has a half-life of 1.5–5
minutes [25]. DAA-I has been shown to be a biased agonist
of the angiotensin AT1 receptor [13], and a recent study by
Szakada´ti et al. [26] shows that internalization of the
angiotensin AT1 receptor is accelerated upon binding by a
biased agonist. This accelerated internalization would also
rapidly remove absorbed DAA-I from the circulation and
contribute to its short systemic sojourn, while simultane-
ously ensuring that DAA-I reaches its target. To confirm
that oral DAA-I enters the systemic circulation in effective
amounts and reaches its target, we anticipate a 2-week
multi-dose phase I study of DAA-I that focuses on mea-
suring PGE2 and PGI2 as surrogate biomarkers of DAA-I.
This multi-dose study would hold much promise, as
chronic oral administration of DAA-I 800 nmole/kg/day
(0.95 mg/kg/day) to mice has been shown to cause a sig-
nificant rise in plasma PGE2 in the animals after 2 weeks of
oral administration [11].
5 Conclusion
This study indicates oral DAA-I is safe and well-tolerated
when administered up to a dose of 1.5 mg/kg. This dose is
more than twice the anticipated anti-diabetic dose of
0.71 mg/kg. In terms of safety and tolerability limits,
preclinical data indicate DAA-I has a very much higher
potential limit: a preclinical toxicological study showed an
oral dose of 23.6 mg/kg to rats had no effect on the blood
pressure and heart of the animals. The absence of a phar-
macokinetic profile after a single oral administration of
DAA-I in human subjects supports the known short sojourn
of DAA-I in the systemic circulation. This puts DAA-I in a
very special class of drugs that are active at ultra-low
concentrations (below the Km of enzymes) and remain
active after the systemic concentration has reverted to basal
level. The internalization of the angiotensin AT1 receptor
upon DAA-I binding and the following biased agonism that
results in the release of PGE2 and PGI2 via a specific COX-
1 pathway [13] indicate that DAA-I holds great promise as
a very specific drug.
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